Labcorp CEO Sells $1.5M as Stock Hits 12-Month High
Labcorp reported a fourth consecutive Q2 EPS beat of $4.99 and raised full-year guidance to $18.10 to $18.55, while free cash flow fell 42% to $314 million against $5.9 billion in total debt. Four exe
Labcorp CEO Sells $1.5M as Stock Hits 12-Month High
NEW YORK, August 26 —
Labcorp Holdings Inc. (LH) shares touched a 12-month high this week after management raised full-year earnings guidance. Q2 free cash flow fell 42% year over year, and CEO Adam Schechter joined three other executives in selling a combined $3.47 million in stock near those highs, with no insider purchases disclosed over the same period.
- Q2 adjusted EPS $4.99, up 14.9% YoY, beat consensus by 4.6%; fourth consecutive beat with widening surprise margins.
- Q2 free cash flow fell to $314M from $543M a year earlier; total debt stands at $5.9B against $142M cash.
- BLS backlog $8.7B with $2.7B expected to convert in 12 months; guidance raised to $18.10 to $18.55.
Margins Expand While Cash Contracts
Labcorp operates two divisions: Diagnostics Laboratories, which runs routine and specialty testing in oncology, genetics, and women's health, and Biopharma Laboratory Services, supporting pharmaceutical and biotech clinical trials. Q2 2026 enterprise revenue of $3.7 billion rose 5.8%, adjusted operating margin expanded 70 basis points to 15.8%, and BLS margins improved 130 basis points after completing Early Development restructuring. Specialty areas including neurology and autoimmune disease delivered double-digit revenue growth in H1 2026. The divergence is in cash: Q2 free cash flow fell to $314 million from $543 million a year earlier, and a 42% year-over-year decline is not what strong adjusted earnings ordinarily produce.
Four Executives, Zero Purchases
Every Form 4 filed by a Labcorp executive over the past 90 days records a sale. CEO Adam Schechter sold 4,669 shares at $320.37 on August 11 for $1.5 million in proceeds; Director Kerrii B. Anderson sold 3,000 shares at $318.02 six days later for $954,060. The CMO and Chief Accounting Officer added further sales, bringing aggregate proceeds to $3.47 million with zero purchases. That uniformity coincides with a $1.4 billion repurchase authorization the board approved in Q2: the company buys at the corporate level while its officers sell personally. The divergence does not prove deterioration, but it raises a legitimate question about conviction at today's price.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| LH | $27.3B | 17.0x | +20.9% |
| DGX | $27.0B | 20.3x | +36.0% |
| WAT | $40.8B | 25.1x | +40.7% |
| UHS | $10.6B | 7.5x | -3.6% |
| IQV | $43.0B | 18.1x | +37.4% |
| MTD | $28.1B | 27.2x | +9.1% |
FCF Recovery Is the Proving Ground
The case for optimism rests on an $8.7 billion BLS backlog, raised full-year EPS guidance, and a reportedly planned Elecsys pTau-217 rollout for Alzheimer's amyloid testing, per this week's reports. PAMA reimbursement pressure on hospital laboratory partners arrives in 2027, and $5.9 billion in debt against $142 million in cash leaves limited cushion. The neutral call holds until Q3 free cash flow either recovers toward prior-year levels or forces management to revisit the timing explanation. Run the free Labcorp Holdings Inc. deep-dive to track the figures, or stress-test the balance sheet with the DCF calculator.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
What did Labcorp report for Q2 2026 earnings?
Labcorp reported Q2 adjusted EPS of $4.99, up 14.9% year over year, beating consensus by 4.6%. Enterprise revenue rose 5.8% to $3.7 billion and adjusted operating margin expanded 70 basis points to 15.8%. Management raised full-year EPS guidance to $18.10 to $18.55.
Why did Labcorp insider selling raise concerns?
Every Form 4 filed by a Labcorp executive over the past 90 days records a sale, with zero purchases disclosed over the same period. CEO Adam Schechter sold 4,669 shares for $1.5 million on August 11, Director Kerrii B. Anderson sold 3,000 shares for $954,060 six days later, and the CMO and Chief Accounting Officer added further sales, bringing aggregate proceeds to $3.47 million. The uniform selling coincides with the company's own $1.4 billion repurchase authorization approved in Q2.
Why did Labcorp free cash flow fall so sharply?
Q2 free cash flow fell to $314 million from $543 million a year earlier, a 42% year-over-year decline. The article notes that a drop of that magnitude is not what strong adjusted earnings ordinarily produce. Q3 free cash flow recovery toward prior-year levels is identified as the key proving ground for the investment case.
What is Labcorp's BLS backlog?
Labcorp's Biopharma Laboratory Services backlog stands at $8.7 billion, with $2.7 billion expected to convert within 12 months. BLS margins improved 130 basis points after the completion of the Early Development restructuring.
What risks does Labcorp face heading into 2027?
PAMA reimbursement pressure on hospital laboratory partners is scheduled to arrive in 2027. Labcorp also carries $5.9 billion in total debt against $142 million in cash, which the article describes as leaving limited cushion if earnings or cash flow disappoint.
Labcorp shares reached a new 12-month high near $336 this week after management raised full-year earnings guidance following a strong Q2 beat, yet CEO Adam Schechter and three other senior executives have sold a combined $3.47 million in stock since early August — all at or near those highs — while free cash flow fell 42% year over year.